Agile Therapeutics Provides Update On Actions Being Taken To Strengthen The Affordable Care Act's No-Cost Contraceptive Coverage Requirement
Portfolio Pulse from Benzinga Newsdesk
Agile Therapeutics (NASDAQ:AGRX) commends efforts to strengthen the ACA's no-cost contraceptive coverage, which could benefit 49 million women. The House Committee on Oversight and Accountability's new report follows actions by the Biden Administration to improve access to contraception. Agile's product, Twirla, could see increased access if the Committee's recommendations are implemented. The report is a follow-up to findings of insurers and PBMs imposing exclusions or cost-sharing, with Vermont lawmakers pushing for enforcement of ACA requirements.
December 12, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agile Therapeutics may benefit from strengthened ACA contraceptive coverage, potentially increasing access to its product Twirla for 49 million women.
The report and subsequent actions by the Biden Administration could lead to increased access to contraceptives, including Agile's Twirla. If the ACA's no-cost coverage is strengthened, it could reduce financial barriers for patients, potentially increasing demand for Twirla. However, the actual impact will depend on the final implementation of these recommendations and regulatory changes.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90